RT Journal Article
SR Electronic
T1 The importance of time post-vaccination in determining the decrease in vaccine efficacy against SARS-CoV-2 variants of concern
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.06.06.21258429
DO 10.1101/2021.06.06.21258429
A1 Yinon Bar On
A1 Elad Noor
A1 Noam Gottlieb
A1 Alex Sigal
A1 Ron Milo
YR 2021
UL http://medrxiv.org/content/early/2021/06/09/2021.06.06.21258429.abstract
AB With the development of high-efficacy vaccines against SARS-CoV-2, an urgent open question is whether currently available vaccines protect with similar efficacy against infection with SARS-CoV-2 variants of concern (VOC). Recent reports quantifying the extent by which VOC can evade vaccine immunity resulted in a range of estimates for the same VOC, which makes them difficult to interpret. One possible explanation for the discrepancies between different studies is an inconsistency in terms of the time post-vaccination of the sampled population. Here we present a model based on the observed correlation between antibody neutralization levels and vaccine efficacy, which demonstrates the impact of time post-vaccination on the comparison of the vaccine efficacy for VOC versus non-VOC infections. Our model predicts and exemplifies several possible consequences for vaccine efficacy in VOC infections: 1) a delay in the onset of vaccine efficacy against VOC; 2) a transient increase in susceptibility to breakthrough infection with VOC compared to non-VOC as a function of time after vaccination. We review preliminary data indicating that such phenomena are observed in studies of the B.1.1.7 and B.1.351 variants. We find that ignoring the strong dependence on the time post-vaccination can lead to contradictory reports of relative efficacy against VOC versus non-VOC, with implications on mitigation strategies against VOC and the design of vaccine efficacy studies.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by the Weizmann CoronaVirus Fund, the Ben B. and Joyce E. Eisenberg Foundation, and by Bill and Melinda Gates Investment INV-018944. Yinon M. Bar-On is an Azrieli Fellow.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No IRB approval is necessaryAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data used in the paper is publicly available in the literature